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Abstract
Chronic obstructive pulmonary disease (COPD) has been traditionally associated with neutrophilic inflammation of the bronchi. 
Studies from the early 1990s demonstrated that eosinophils may also migrate into the lower airways of patients with COPD and 
their increased numbers can be noticed during exacerbations as well as stable disease. Eosinophilic phenotype of COPD is cha-
racterized by several unique features, i.e. a specific pattern of airway inflammation and distinct clinical course or susceptibility to 
corticosteroid treatment. In this paper, we present an up-to-date review of the literature on clinical characteristics of eosinophilic 
COPD, as well as the role of eosinophils as a biomarker-guided therapy in COPD.
Key words: COPD, eosinophils, biomarkers
Adv. Respir. Med. 2017; 85: 271–276
Introduction
Chronic Obstructive Pulmonary Disease 
(COPD) is one of the most frequent chronic di-
seases in adults and one of the main causes of 
morbidity and mortality. Data on the worldwide 
prevalence of COPD has been provided by the 
Burden of Obstructive Lung Disease (BOLD) study. 
Based on these results, the prevalence of COPD 
at Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) stage 2 or higher was estimated 
at 10.1% overall, with a number of regional diffe-
rences [1]. In Poland, the Małopolska Region, the 
estimated population prevelance of COPD was 
22.1%, whereas 10.9% of the subjects had COPD 
GOLD stage ≥ 2 [2]. 
Cigarette smoke exposure is a  well-reco-
gnized risk factor in the development of COPD. 
Cigarette smoke leads to activation of pro-inflam-
matory cascades resulting in lung injury. It is 
generally accepted that the neutrophilic inflam-
mation observed in the lungs of COPD patients is 
intrinsically linked to the tissue destruction and 
alveolar airspace enlargement, leading to disease 
progression [3]. However, a  subset of patients 
with COPD develops eosinophilic inflammation 
in the airways that is reflected also in increased 
blood eosinophil number. A growing body of 
evidence suggests that eosinophilic COPD is 
a distinct phenotype of the disease. Eosinophilic 
COPD could be labelled as a part of asthma-COPD 
overlap (ACO), a condition sharing pathophysio-
logical and clinical features of both asthma and 
COPD. However, a  recent study demonstrated 
that eosinophilic COPD patients have distinct 
characteristics compared to COPD patients with 
a history of asthma, i.e. they are characterized by 
little evidence of allergies and less exacerbations, 
but more pronounced eosinophilic inflammation 
[4]. Here, we present a review of the literature on 
clinical characteristics of eosinophilic COPD, as 
well as the role of eosinophils in a biomarker-
guided therapy in COPD.
Eosinophilic inflammation in COPD
Although COPD has been considered a con-
dition characterized by neutrophilic airway in-
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flammation, as early as in the 1990s, the concept 
of eosinophilic inflammation arose. In 1994, 
Saetta et al. [5] showed that patients with chronic 
bronchitis at exacerbation had significantly more 
eosinophils in sputum and bronchial biopsies 
than subjects examined at stable disease. Further 
studies revealed that the influx of eosinophils 
into the airways is rather associated with viral 
exacerbations, whereas during bacterial infec-
tions a decrease in blood and sputum esoinophils 
occurs [6, 7].
Evidence implicating eosinophils in airway 
inflammation in stable COPD was presented by 
Balzano et al. [8] who compared sputum cell com-
position and eosinophil cationic protein (ECP) 
levels between clinically stable COPD subjects, 
healthy smokers, mild asthmatics and healthy 
subjects. The authors showed that sputum eosin-
ophil percentage was increased in patients with 
COPD, as compared with healthy controls. Spu-
tum ECP levels were significantly higher in both 
COPD and asthma than in the other two groups. In 
patients with COPD and asymptomatic smokers, 
considered as a whole, eosinophil percentage and 
ECP concentrations correlated negatively with 
FEV1 % predicted and FEV1/FVC ratio.
A complex clinical characteristics of COPD 
subjects with evidence of eosinophilic inflam-
mation was provided by the ECLIPSE study 
(Evaluation of COPD Longitudinally to Identify 
Predictive Surrogate End-points) [9]. The data 
is valuable not only due to the size of the study 
group, but also the 3-year follow-up period which 
provided an opportunity to assess stability of 
eosinophilic COPD phenotype. Blood samples 
for eosinophil counts were obtained from 1483 
subjects at a baseline and then yearly over the 
observation period. 37.4% of the subjects had 
eosinophil counts persistently ≥ 2% at all visits, 
13.6% had eosinophil counts persistently ≤ 2% 
at all visits, and 49% subjects had variable eo-
sinophil counts. COPD subjects with eosinophil 
counts persistently ≥ 2% were slightly older, had 
a greater proportion of males and fewer current 
smokers than other COPD groups. They were also 
characterized by a higher FEV1 % predicted and 
fat-free mass index, lower St. George’s Respira-
tory Questionnaire (SGRQ), modified Medical 
Research Council (mMRC) scores, and BODE 
(body mass index, airflow obstruction, dyspnea, 
exercise capacity) index. 
There is little knowledge about the mecha-
nism leading to the development of eosinophil 
infiltration in the airways of some COPD subjects, 
as well as differences in systemic and airway 
inflammation pattern between eosinophilic and 
non-eosinophilic COPD. In a recent study, Kolsum 
at al. [10] assessed the nature of airway inflamma-
tion in patients with COPD based on blood eosin-
ophil numbers. The study subjects were classified 
according to blood eosinophil counts as “eosino-
phil low” or “eosinophil high’ (< 150 cells/μL or 
> 250 cells/μL respectively). “Eosinophil high” 
patients had also higher eosinophil numbers 
in sputum, bronchoalveolar lavage (BAL) and 
bronchial submucosa. This was accompanied by 
higher sputum interleukin(IL)-5 and haptoglobin 
levels, as well as CCL20 and CCL24 concentra-
tions in BAL. “Eosinophil high” subjects were 
also characterized by more pronounced airway 
remodelling as indicated by increased reticular 
basement thickness and tenascin thickness, as 
well as increased BAL metalloproteinase-7 and -9 
concentrations. In addition, our group reported 
that IL-33, one of so-called “epithelium derived 
cytokines” extensively examined in allergic asth-
ma in the past few years, might be involved in the 
pathogenesis of eosinophilic COPD. IL-33 is an 
alarmingly critical for eosinophil differentiation, 
maturation, activation and survival, produced 
by epithelial cells in response to danger signals 
[11]. Our preliminary data demonstrated that 
serum and sputum IL-33 concentrations are sig-
nificantly elevated in COPD patients with sputum 
eosinophil counts > 3% versus patients without 
airway eosinophilia [12]. Moreover, IL-33 serum 
and sputum levels correlated positively with 
sputum eosinophil percentage. Hence, IL-33 may 
be implicated in the development of eosinophilic 
phenotype of COPD. It is plausible that other cells 
and cytokines released by epithelial cells and/or 
airway smooth muscles may play a  role in the 
development of airway eosinophilia in a simi-
lar mechanism to that observed in eosinophilic 
asthma (Fig. 1). 
Several studies assessed fractional exhaled 
nitric oxide (FeNO) as a surrogate marker of eosin-
ophilic airway inflammation in COPD. According 
to the available data, FeNO correlated positively 
with sputum but not blood eosinophils at exac-
erbation and in lesser extent at recovery [13, 14]. 
In addition, FeNO levels determined at hospital 
admission may predict the overall response to 
corticosteroid treatment in COPD patients with 
acute exacerbations [10]. However, no difference 
in FeNO levels between high and low eosinophil 
counts patients with stable COPD was detected 
[10]. Thus, FeNO may reflect eosinophil accu-
mulation in the airways during exacerbation and 
therefore may help guide therapeutic decisions. 
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Eosinophilia and risk and clinical course  
of COPD exacerbations
The role of eosinophils as a biomarker pre-
dicting risk of COPD exacerbations and response 
to treatment has been of considerable interest. In 
a large study including 7225 patients with COPD 
defined from Copenhagen General Population 
Study, Vedel-Krogh et al. [15] examined an asso-
ciation between baseline blood eosinophil counts 
and risk of exacerbations, defined as moderate 
(short course treatment with systemic cortico-
steroids) or severe (hospitalization). COPD was 
defined basing on spirometry as FEV1/FVC ratio < 
70%. The authors also assessed exacerbation risk 
in a subgroup of 203 individuals with “clinical 
COPD”, described as participants with a smoking 
history of at least 10 pack-years, FEV1 less than 
70% of predicted value, and at least one mode-
rate or severe exacerbation in the year before 
a baseline. Among all participants with COPD, 
blood eosinophils above 0.34 × 109 cells/l were 
associated with 1.76-fold increase in incidence 
rate for severe exacerbations and 1.15-fold for 
moderate exacerbations. Corresponding values in 
those with “clinical COPD” were 3.21 and 1.69. In 
contrast, using a cut point of 2% for blood eosi-
nophils, the risk of exacerbations was increased 
for severe exacerbations only among individuals 
with “clinical COPD”. These results suggest that 
elevated blood eosinophil absolute number is 
a better predictor of exacerbations than percen-
tage values, and the narrower COPD definition, 
the stronger association between exacerbation 
rate and eosinophils can be noticed.
In a metaanalysis of three clinical trials, 
Bafadhel et al. [16] evaluated effectiveness of 
treatment COPD exacerbations with oral cor-
ticosteroids in respect of blood eosinophilia. 
The primary outcome was the rate of treatment 
failures following treatment of an exacerbation, 
defined as retreatment, hospitalization or death 
within 90 days of randomization. The subjects 
were grouped according to treatment allocation 
(prednisolone or non-prednisolone) and blood 
eosinophil count (< 2% or ≥ 2%) at the time of 
exacerbation. The treatment failure rate was 66% 
in patients with a blood eosinophil count ≥ 2% 
who did not receive prednisolone and 11% in 
those who did. In patients with a blood eosinophil 
Figure 1. Some of possible mechanisms leading to the development of eosinophilic inflammation in COPD. Airway epithelium produces thymic 
stromal lymphpoietin (TSLP), interleukin (IL)-25 and IL-33 in response to danger signals, e.g. cigarette smoke and infections. Airway smooth 
muscles also produce IL-33 and TSLP when exposed to cigarette smoke. The three cytokines are directly involved in eosinophil (Eos) activation 
and migration into the airways. They also activate innate lymphoid cells type 2 (ILC2), an abundant source of IL-5. In addition, they increase lung 
homing of hemopoietic progenitor cells (HPC), stimulate HPC to produce IL-5 and orchestrate so called “hemopoiesis in situ”, i.e. transformation 
of HPC into mature eosinophils in the airways
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count < 2%, there was no difference in treatment 
failure rates with and without prednisolone (26% 
vs 20%). The findings were not modified by se-
verity of the exacerbation, baseline exacerbation 
lung function, age or smoking history. The authors 
concluded that a  eosinophil-directed cortico-
steroid treatment strategy using the peripheral 
blood eosinophil count measured at the onset of 
exacerbation is a promising approach to maximize 
benefit and minimize harm in COPD.
A recent study on a group of patients hospi-
talized due to COPD exacerbation demonstrated 
that blood eosinophil level ≥ 200 cells/μL and/
or ≥ 2% of the total white blood cell count on 
admission was associated with 3.59-fold increase 
in the risk of 12-month COPD-related readmis-
sion, 2.32-fold increase in the risk of 12-month 
all-cause readmission, and 2.74-higher chance of 
a shorter time to first COPD-related readmission 
but not with the length of stay [17]. The study 
also showed that readmission rate increased 
proportionally to eosinophil cell count. On the 
contrary, in another study using similar criteria 
for blood eosinophilia, the mean length of stay 
was significantly shorter in patients with eosino-
philic than with non-eosinophilic exacerbations 
(5.0 days vs 6.5 days), whereas readmissions rates 
were similar in both groups [18]. 
The results of the above mentioned reports 
support the notion that peripheral blood eosino-
phil count can be a biomarker in COPD and a va-
luable predictor of the response to the treatment 
of exacerbations. 
Exacerbation prevention in eosinophilic COPD
As mentioned above, COPD patients with 
high blood eosinophil counts are at increased 
risk of exacerbations, especially severe ones [15]. 
One must remember that exacerbation in a COPD 
patient is a major event leading to accelerated 
lung function decline. Moreover, frequent exacer-
bations increase mortality risk and 50% of COPD 
patients will die within 5 years since severe aggra-
vation [19]. Therefore, exacerbation prevention is 
essential in COPD management. 
Studies proved that ICS treatment reduces 
risk of COPD exacerbations. Early trials using 
sputum eosinophil count-guided COPD therapy 
demonstrated that a management strategy aiming 
to minimize eosinophilic airway inflammation by 
doubling the dose of ICS in patients with sputum 
eosinophils > 3%, is associated with a significant 
reduction, by 62%, in the frequency of severe, 
but not mild or moderate, COPD exacerbations 
compared with patients treated according to 
traditional guidelines [20]. Subsequent studies 
reported that sputum eosinophils highly correlat-
ed with blood eosinophil count and therefore 
rendered sputum-guided therapy pointless [21]. 
Indeed, large clinical trials proved that blood 
eosinophilia is a useful biomarker of the effect of 
ICS treatment on COPD exacerbations. A post-hoc 
analysis of data from two replicate, randomized, 
double-blind trials of 12-month duration, in 
which vilanterol once daily was compared with 
vilanterol plus 50 μg, 100 μg, or 200 μg flutica-
sone furoate in patients with moderate-to-severe 
COPD and a history of one or more exacerbation 
in the previous year [22]. Across all doses of 
inhaled corticosteroids, fluticasone furoate and 
vilanterol significantly reduced exacerbations 
by 29% compared with vilanterol alone (mean 
0.91 vs 1.28 exacerbations per patient per year) 
in patients with eosinophil counts ≥ 2%, and 
non-significantly by 10% (0.79 vs 0.89) in patients 
with eosinophil count ≤ 2%. Reduction in exac-
erbations increased along with the percentage of 
blood eosinophils reaching 42% in patients with 
eosinophil count ≥ 6%. Recently, a post-hoc anal-
ysis of the FORWARD study, a randomized, dou-
ble-blind, parallel group trial that compared 48 
weeks of treatment with extrafine beclomethasone 
dipropionate plus formoterol fumarate (BDP/FF), 
100/6 mg, two inhalations twice a day, versus FF 
12 mg, one inhalation twice a day, in patients 
with severe COPD and a history of exacerbations, 
demonstrated that the higher blood eosinophil 
count, the greater reduction in exacerbations, 
reaching 46% in patients with blood eosinophil 
number more than 279.8 cells/μl [23]. Notewor-
thily, withdrawal of ICS in patients with severe to 
very severe COPD and blood eosinophil counts ≥ 
4% or ≥ 300 cells/μL before the ICS treatment was 
introduced, have led to a higher risk of exacerba-
tions compared to a group of patients continuing 
ICS treatment [24]. 
Unfortunately, although inhaled steroid 
treatment can reduce exacerbation rate in COPD 
patients with high blood eosinophils count, it 
is associated with increased risk of pneumo-
nia. This phenomenon was first reported in 
the TORCH (TOwards a Revolution in COPD 
Health) study, among COPD patients receiving 
fluticasone propionate alone or in combination 
with salmeterol, and later confirmed by other 
studies [25]. Further evidence pointed out that 
the greatest risk of pneumonia can be seen in 
patients treated with a daily fluticasone-equiva-
lent dose > 1000 μg [26]. A subsequent Cochrane 
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Database systematic review demonstrated that 
not only fluticasone but also budesonide, deliv-
ered alone or in combination with a long-acting 
ß2-agonist (LABA), is associated with increased 
risk of serious adverse pneumonia events [27]. 
A 2-fold increase in pneumonia incidence was 
also observed during treatment with beclometh-
asone/formoterol [28]. In addition, a post-hoc 
analysis of ten clinical trials demonstrated than 
COPD subjects with blood eosinophil counts ≥ 2% 
are slightly less likely to have pneumonia when 
not treated with inhaled corticosteroids (3.8% of 
patients with < 2% of blood eosinophil counts 
versus 2.4% with ≥ 2% of blood eosinophils) [29]. 
In patients treated with inhaled corticosteroids, 
pneumonia events occurred in 4.5% versus 3.9% 
in those not treated with corticosteroids.
Some data suggest that long-acting anti-mus-
carinic agent (LAMA)/LABA combination treat-
ment might be a new option to decrease exacer-
bation risk without increasing risk of pneumonia 
associated with ICS therapy, even in patients with 
eosinophilic COPD. Indeed, results of the FLAME 
study, comparing indacaterol/glycopyrronium 
110/50 μg with salmeterol/fluticasone combina-
tion 50/500 μg in patients with ≥ 1 exacerbation in 
the preceding year demonstrated that once-daily 
long-acting b2-agonist/long-acting muscarinic 
antagonist provides superior or similar benefits 
over twice-daily long-acting b2-agonist/inhaled 
corticosteroid regardless of blood eosinophil 
levels in patients with COPD [30]. However, this 
finding needs to be further confirmed.
Biologics in the treatment of eosinophilic COPD
Many monoclonal antibodies have been 
developed for treatment of eosinophilic asthma 
and some of them are assumed to have thera-
peutic potential in the treatment of eosinophilic 
COPD as well. 
A phase 2 trial tested the safety and efficacy 
of benralizumab, an anti-IL-5 receptor antibody, 
in eosinophilic COPD defined as sputum eosino-
phil counts > 3%. In this study, benralizumab 
did not reduce the exacerbation rate nor modified 
lung function. However, a subgroup analysis reve-
aled a trend toward an improvement in FEV1 and 
exacerbations in patients with a baseline blood 
eosinophil number greater than 200 cells/μl and 
treated with benralizumab. Recently, results of 
a pilot study on the treatment of eosinophilic 
COPD (sputum eosinophil counts ≥ 3%) with me-
polizumab have been published [31]. Six-month 
treatment with mepolizumab significantly redu-
ced sputum and blood eosinophil counts, an effect 
not seen in placebo treated subjects. However, 
anti-IL-5 treatment did not affect lung function, 
exacerbation rates, and quality of life scores, sug-
gesting that eosinophils may not play a relevant 
pathobiological role in COPD. The main limitation 
of the study was a small number of participants, 
i.e. 8 patients receiving active treatment and 
9 subjects in placebo group. Therefore, drawing 
a final conclusion based on such limited data 
would be premature. Results of a just completed 
large clinical trial evaluating efficacy and safety 
of mepolizumab in severe COPD patients with 
frequent exacerbations will provide substantially 
more information on the subject [32].
Thus, additional studies are warranted to 
evaluate the efficacy of anti-eosinophil therapy 
and its effects on clinical parameters such as 
exacerbation rate in COPD. Apart from anti-IL-5 
therapies, biologics neutralizing other cytokines 
critical for eosinophil differentiation, maturation, 
activation and survival may be an interesting 
target. Potential molecules of interest include 
“epithelium derived cytokines”, i.e. IL-25, IL-33 
and TSLP, traditionally associated with Th2-li-
ke conditions. Results of our above mentioned 
study demonstrating overexpression of IL-33 in 
COPD suggest that there are still some potential 
targets for biological therapies that may improve 
treatment outcomes of COPD, in particular eosi-
nophilic phenotype of the disease.
Summary
A growing body of evidence suggests that 
eosinophilic COPD is a  separate phenotype of 
the disease with distinct clinical features. Simple 
laboratory test such as blood differential count 
may identify patients with eosinophilic inflam-
mation. It is important to do so as subjects with 
blood and/or airway eosinophilia are more likely 
to suffer from exacerbations, yet better respond to 
treatment with corticosteroids. However, COPD 
subjects treated with inhaled corticosteroids are 
at increased risk of pneumonia. New treatment 
approach with biologic agents is expected to be 
unencumbered by such a side effect. Nonethe-
less, therapies targeting IL-5 pathway have been 
investigated showing no clear benefit so far in 
regard of exacerbation risk reduction and impro-
vement in other clinical parameters. More studies 
are warranted to confirm if neutralizing other 
cytokines crucial for eosinophil differentiation 
and activation may be beneficial in treatment of 
patients with eosinophilic COPD. 
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